Application of exosome PACAP in preparation of medicine for diagnosing AD
By detecting the PACAP protein in exosomes from nervous system origin, the problem of the inability to directly detect the PACAP level of AD in the prior art is solved, and a convenient and efficient diagnosis of Alzheimer's disease is achieved, with good diagnosis Specificity and sensitivity.
Patent Information
- Application Number
- CN202310610465.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-26
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to directly detect PACAP levels in Alzheimer's disease (AD) through peripheral blood. Because the PACAP protein cannot cross the blood-brain barrier, it lacks effective diagnostic methods.
The concentration of PACAP-38 or PACAP-27 was determined by detecting the PACAP protein in exosomes from nervous system origin, including extracting exosomes from the subject's peripheral blood, enriching with NCAM or L1CAM antibodies and determining the concentration of PACAP-38 or PACAP-27 by PACAP-ELISA reagent , establish a diagnostic curve to judge AD risk.
It realizes convenient acquisition of samples in peripheral blood, has good diagnostic specificity and sensitivity, and promotes the application of methods to diagnose AD, avoiding the limitations of traditional cerebrospinal fluid acquisition and expensive PET-CT detection.
Smart Images

Figure CN119023969A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine and relates to the use of exosome PACAP in preparing a reagent for diagnosing AD. Background Art
[0002] Alzheimer's disease (AD) has caused a serious socioeconomic burden in China and even globally. 1,2 . As the aging population in society intensifies, there is an urgent need to further understand the pathogenesis of AD and its early diagnosis and treatment methods. Due to the lack of effective means to treat dementia, many new drug trials for the treatment of cognitive impairment in the past two decades have been aborted for various reasons. Hundreds of AD treatments have been tested in clinical trials, but only six have been authorized and widely used for AD treatment. 3-8 There is increasing evidence that dementia may be prevented through early intervention, which has attracted international attention to early diagnosis and intervention. It is urgent to seek new diagnostic and treatment options.
[0003] Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neurotrophic protective peptide 9 , which plays a subsequent role by activating adenylate cyclase 10,11 PACAP has two forms, one with a full length of 38 amino acids (PACAP-38) and one with 27 amino acids (PACAP-27). 12 Among them, PACAP-38 is the major form of PACAP in the brain.
[0004] Professor Shi Jiong's team found that PACAP deficiency is associated with the severity of AD pathology 13 , decreased PACAP levels were found in the cerebrospinal fluid, superior frontal gyrus and middle temporal gyrus tissues of AD patients, and the PACAP level was inversely proportional to the severity of dementia, but there was no significant change in PACAP in the cerebrospinal fluid of patients with Parkinson's disease (PD) and frontotemporal dementia (FTD). This result confirms the importance of PACAP as a new diagnostic marker for Alzheimer's disease 14 .
[0005] Although PACAP has been confirmed to be of diagnostic significance for AD, previous studies have mostly found decreased PACAP levels in the cerebrospinal fluid or brain tissue of AD patients. 9 , so it is not possible to use peripheral blood for direct testing.
[0006] Therefore, there is still a need to develop new methods for diagnosing AD. Summary of the invention
[0007] Through in-depth research and creative work, the inventors surprisingly found that by detecting PACAP in exosomes derived from the nervous system, Alzheimer's disease can be effectively diagnosed and has good application prospects. The following invention is provided:
[0008] One aspect of the present invention relates to use of PACAP protein in exosomes derived from the nervous system or a reagent for detecting PACAP protein in exosomes derived from the nervous system in the preparation of a medicament for diagnosing Alzheimer's disease.
[0009] In some embodiments of the present invention, in the use, the exosomes derived from the nervous system are brain-derived exosomes such as pituitary-derived exosomes.
[0010] In some embodiments of the present invention, in the use, the amino acid sequence of the PACAP protein is as shown in SEQ ID NO:1 and / or SEQ ID NO:2.
[0011] The main target of the present invention is PACAP-38, and the specific sequence is shown below.
[0012] Amino acid sequence of PACAP-38:
[0013] KNKVRQKYRKGLVAALYKKVAMQKRYRSYSDTFIGDSH(SEQ ID NO:1)
[0014] Amino acid sequence of PACAP-27:
[0015] LVAALYKKVAMQKRYRSYSDTFIGDSH(SEQ ID NO:2)
[0016] In some embodiments of the present invention, the use, wherein the reagent for detecting PACAP protein in exosomes derived from the nervous system comprises:
[0017] (1) Reagents for extracting exosomes from the peripheral blood of a subject;
[0018] (2) Reagents for isolating or enriching exosomes derived from the nervous system; and / or
[0019] (3) Reagents for measuring the concentration or content of PACAP protein.
[0020] In some embodiments of the present invention, the use, wherein in item (1), the reagent for extracting exosomes from the peripheral blood of a subject comprises Exoquick reagent.
[0021] In some embodiments of the present invention, the use, wherein in item (2), the reagent for separating or enriching exosomes derived from the nervous system comprises NCAM antibody or L1CAM antibody.
[0022] In some embodiments of the present invention, the use, wherein in item (3), the reagent for determining the concentration or content of PACAP protein includes an ELISA reagent or an immunoblotting reagent for determining PACAP.
[0023] In some embodiments of the present invention, the use, wherein the PACAP protein concentration of the subject is compared with the cutoff value of the receiver operating curve of the exosomal PACAP protein concentration between AD and non-AD control groups:
[0024] If the subject's PACAP protein concentration was greater than or equal to the cutoff value, the risk of AD was judged to be high;
[0025] If the subject’s PACAP protein concentration is less than the cutoff value, the risk of AD is judged to be low;
[0026] Preferably, the number of AD subject samples and non-AD subject samples for drawing the working curve is independently greater than or equal to 10, greater than or equal to 20, greater than or equal to 30, greater than or equal to 50, greater than or equal to 80, greater than or equal to 100, greater than or equal to 200 or greater than or equal to 500.
[0027] In some embodiments of the present invention, the use, wherein:
[0028] If the subject's PACAP protein concentration is greater than or equal to the threshold, the risk of AD is judged to be high;
[0029] If the subject’s PACAP protein concentration is less than the threshold, the risk of AD is judged to be low;
[0030] Preferably, the threshold value is 4.5-5.5 ng / mL, 4.6-5.4 ng / mL, 4.7-5.3 ng / mL, 4.8-5.2 ng / mL, 4.9-5.1 ng / mL, 4.9-5.0 ng / mL, 4.9 ng / mL or 4.9412 ng / mL.
[0031] In some embodiments of the present invention, the use, wherein:
[0032] If the PACAP protein concentration of the subject is greater than or equal to that of the healthy subject, the risk of AD is judged to be higher;
[0033] If the PACAP protein concentration of the subject is lower than that of a healthy subject, the risk of AD is judged to be lower.
[0034] In the present invention,
[0035] The gold standard for AD diagnosis is the NIA-AA diagnostic criteria 15 , mainly focusing on the core pathological Aβ and tau proteins of AD, relying on cerebrospinal fluid content examination and positron emission tomography (PET-CT) 16 Complete the test. The core marker is Aβ, which is often used 11 C-benzothiazole tracer Pittsburgh compound B (PiB) PET-CT detection, many studies have confirmed its diagnostic significance 17-19 The latest "2020 Edition of China's Alzheimer's Disease and Dementia Diagnosis and Treatment Guidelines" also recommends PiB PET-CT as one of the diagnostic tests. 20 .
[0036] Without being bound by theoretical limitations, the commonly used diagnostic method of obtaining cerebrospinal fluid to detect target proteins requires lumbar puncture, which is invasive. Elderly AD patients often have poor cooperation and difficulty in obtaining specimens. The relatively convenient PET-CT test is expensive. In addition, the use of mass spectrometry to directly detect tau protein and Aβ in peripheral blood, although it solves the problem of easy specimen collection, is limited by the high cost of the equipment used and the low popularity.
[0037] At present, the main extraction method for exosomes to assist in the diagnosis of various diseases is high-throughput particle precipitation method. 21 That is, using Exoquick reagent to effectively separate total extracellular vesicles from plasma or serum samples, and then using biotinylated antibodies against surface markers of target tissues / organs for immunoprecipitation, and performing secondary extraction of whole exosomes to obtain exosomes secreted by target tissues / organs for subsequent detection. NCAM antibodies or L1CAM antibodies are mostly used in the nervous system. These two antibodies target NCAM protein and L1CAM protein, respectively. These two proteins are very common in the nervous system. NCAM (neural cell adhesion molecule, CD56) is an adhesion glycoprotein. NCAM regulates neural attachment, axon extension and cell-to-cell interactions through homologous and heterochromatic interactions. Neural cell adhesion molecule L1 (L1CAM) is a single-pass transmembrane glycoprotein member of the immunoglobulin superfamily. L1CAM is mainly expressed in brain cells and plays an important role in the development of the nervous system. It is involved in neurite bundling and growth, myelination, neuronal migration and neuronal cell adhesion. 22,23-26Because of their overexpression and relatively specific expression in neural tissue and early studies showing overexpression on exosomes derived from cultured neurons 27 Previous studies have confirmed the feasibility of NCAM antibody enrichment of peripheral brain-derived exosomes. 28-29 This method has been proven to be stable in extracting vesicles. Through nanoparticle tracking analysis, researchers found that the size distribution of extracellular vesicles enriched by L1CAM antibodies was similar to that of total plasma extracellular vesicles, which confirmed that the vesicle size and morphological characteristics of the extracted extracellular vesicles met the requirements. In addition, in order to evaluate the success of immunoprecipitation, this research method has been verified by immunoelectron microscopy to confirm the feasibility of the antibody target. 30 .
[0038] With the increasing attention paid to exosomes, more extraction methods have gradually emerged. The main methods for in vitro extraction of exosomes include ultracentrifugation, density gradient centrifugation, chromatography, magnetic bead immunocapture, etc. After extraction, cell surface markers are analyzed, proteins are analyzed by methods such as protein immunoblotting and enzyme-linked immunosorbent assay, or by qPCR and next-generation sequencing to encode 31 or by analyzing miRNA carried by exosomes through plasmon ultrasensitive biosensors based on advanced plasmon structures assembled from DNA (capable of selectively detecting single nucleotides at the molar level). 32 New methods also include flow cytometry and immunoblotting 33 and surface plasmon resonance imaging-based biosensors to identify and analyze neural extracellular vesicle populations circulating in the plasma of AD patients and healthy subjects 34 Although new methods continue to emerge, in general, methods for isolating exosomes using high-throughput particle precipitation (also known as immunoprecipitation) provide greater yields of target exosomes with less impurities compared to the gold standard ultracentrifugation procedure. 30 .
[0039] In the present invention, regarding the term "exosomes": According to the definition of the International Society for Extracellular Vesicles in 2018, exosomes are a type of extracellular vesicles, where extracellular vesicles (EVs) are naturally released from cells, separated by lipid bilayers and cannot replicate, do not contain a functional nucleus, and have different secretion modes and different sizes. 35 Alternatively, exosomes are generally considered to be a type of extracellular vesicles secreted through intracellular multivesicular bodies. 35,36 , with a diameter between 50-100nm or 30-100nm 36 .
[0040] Advantageous Effects of the Invention
[0041] The present invention achieves one or more of the following technical effects:
[0042] (1) The peripheral blood samples used for diagnosis are easy to obtain, and only relevant tests need to be performed on the peripheral blood of the subjects;
[0043] (2) The testing instruments used are relatively conventional and can be completed in most medical institutions and testing agencies;
[0044] (3) It has good diagnostic specificity and sensitivity and is worth promoting. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 : Experimental flow chart.
[0046] Figure 2 : The concentration of exosomal PACAP between AD and non-AD control groups. The figure shows that there is a significant difference in the concentration of exosomal PACAP between AD and non-AD control groups.
[0047] Figure 3 : Receiver operating curve of exosomal PACAP concentration between AD and non-AD control groups. The area under the curve is 0.908, P<0.001, indicating that exosomal PACAP concentration has a good diagnostic efficacy for AD. DETAILED DESCRIPTION
[0048] The embodiments of the present invention will be described in detail below in conjunction with the examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific conditions are specified in the examples, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.
[0049] Embodiment 1:
[0050] 1. Experimental Methods
[0051] (1) Subject enrollment and assessment:
[0052] The experimental design is a case-control study. The inventors will mainly collect patients considered for diagnosis of Alzheimer's Disease (AD) and non-AD control groups. Continuous enrollment was carried out at Beijing Tiantan Hospital affiliated to Capital Medical University and other clinical research centers, and patient enrollment lasted from September 2019 to October 2021. Inclusion criteria: ① People aged 40-100; ② Can cooperate with relevant information collection and clinical evaluation; ③ Exclude other diseases that can cause cognitive impairment, etc.; ④ Exclude recent use of drugs that interfere with exosome detection, etc.; ⑤ Can cooperate with fasting peripheral blood for subsequent sample testing.
[0053] Among the enrolled population, their comprehensive medical history, clinical manifestations, blood test results, cognitive assessment, head structure imaging, and PIB PET-CT results were collected and evaluated. According to the NIA diagnostic criteria, subjects who met the AD diagnosis criteria were enrolled in the AD group, and subjects who met the non-AD diagnosis criteria were enrolled in the non-AD control group. For the specific process, see Figure 1 The information of the enrolled subjects is shown in Table 1 below.
[0054] (2) Specimen collection and processing:
[0055] 2 mL of fasting peripheral blood was drawn using a non-anticoagulant tube to detect the PACAP concentration in neural exosomes.
[0056] Freshly collected untreated blood samples were promptly sent to the designated laboratory for serum extraction. During the extraction, the samples were allowed to stand at room temperature for 20-30 minutes, centrifuged at 1500g / min for 10 minutes to obtain the supernatant, which was stored in a 0.5mL cryotube and stored in a -80℃ refrigerator. Pay attention to balancing during the centrifugation process. The samples were then transported to Beijing Tiantan Hospital by cold chain for centralized storage and data analysis. They were used for subsequent experiments.
[0057] 300 μL of serum was collected from each patient, and the whole exosomes were obtained by high-throughput particle precipitation method using Exoquick reagent (SBI, EXOQ20A-1). The operation was carried out according to the reagent instructions.
[0058] Subsequently, brain-derived exosomes were enriched by biotinylated NCAM antibody (Santa Cruz, sc-106) (Themo, A39256) and precipitated by streptavidin (Themo, SA10004); the operation was carried out according to the reagent instructions;
[0059] Extract the contents of enriched exosomes as follows:
[0060] 1) Each pellet was suspended in 50 μL of 0.05 M glycine-HCl (pH 3.0) by vortexing for 10 s;
[0061] 2) Each suspension received 0.45 ml DPBS containing 2 g / 100 ml BSA, 0.10% Tween 20 and inhibitor cocktail;
[0062] 3) Incubate at 37°C with vortexing for 10 minutes and store at -80°C before ELISA.
[0063] The concentration of PACAP in peripheral blood was detected using a PACAP-ELISA kit (MyBioSource.com, MBS160511); the operation was performed according to the instructions of the kit.
[0064] 2. Experimental results
[0065] The results are shown in Tables 1 to 3. Figures 2 to 3 shown.
[0066] Table 1: Basic information of AD group and non-AD control group
[0067]
[0068] Table 2: Logistic regression results of exosomal PACAP concentration on diagnosis of AD
[0069]
[0070] Note: The regression equation controls for age and gender.
[0071] Table 3: Receiver operating curves of exosomal PACAP concentration for AD
[0072]
[0073] The results show:
[0074] (1) There was no significant statistical difference in age, gender, and years of education between the AD group and the non-AD control group. The exosomal PACAP concentration in the AD group (3.99±1.01 ng / mL) was significantly lower than that in the non-AD control group (6.78±1.82 ng / mL), P<0.001 (Table 1, Figure 2 ). After adjusting for age and gender factors, the logistic regression equation further revealed that the OR value and 95% CI of exosomal PACAP concentration for AD were 0.278, [0.175, 0.443], P < 0.001 (Table 2).
[0075] (2) Using the receiver operating curve ( Figure 3) The diagnostic efficacy of exosomal PACAP concentration for AD was analyzed. The results showed that exosomal PACAP concentration had a good diagnostic effect on AD, and its optimal cutoff point was 4.9412 ng / mL. The sensitivity of this cutoff point for AD diagnosis was 84.8%, the specificity was 85.5%, the area under the curve and 95% CI were 0.908, [0.852, 0.963], P < 0.001.
[0076] References:
[0077] 1.International AsD.World Alzheimer's Report 2021:Journey through the diagnosis of dementia.2021.
[0078] 2. Ren Rujing, Yin Peng, Wang Zhihui, et al. China Alzheimer's Disease Report 2021. Diagnostics Theory & Practice 2021;20:317-337.
[0079] 3. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology1998; 50:136-45.
[0080] 4. M, Anand R, Cicin-Sain A et al. Efficacy and safety ofrivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ 1999;318:633-8.
[0081] 5.Wilcock GK,Lilienfeld S,Gaens E.Efficacy and safety of galantaminein patients with mild to moderate Alzheimer's disease:multicentre randomisedcontrolled trial.Galantamine International-1Study Group.BMJ 2000;321:1445-9.
[0082] 6.van Dyck CH,Tariot PN,Meyers B,Malca Resnick E.A24-week randomized,controlled trial of memantine in patients with moderate-to-severe Alzheimerdisease.Alzheimer Dis.Assoc.Disord.2007;21:136-43.
[0083] 7.Xiao S,Chan P,Wang T et al.A 36-week multicenter,randomized,double-blind,placebo-controlled,parallel-group,phase 3clinical trial of sodiumoligomannate for mild-to-moderate Alzheimer's dementia.AlzheimersRes.Ther.2021;13:62.
[0084] 8.Alexander GC,Emerson S,Kesselheim AS.Evaluation ofAducanumab forAlzheimer Disease:Scientific Evidence andRegulatory Review InvolvingEfficacy,Safety,and Futility.Jama 2021;325:1717-1718.
[0085] 9.Vaudry D,Falluel-Morel A,Bourgault S et al.Pituitaryadenylatecyclase-activating polypeptide and its receptors:20 yearsafter thediscovery.Pharmacol.Rev.2009;61:283-357.
[0086] 10.Vaudry D,Falluel-Morel A,Bourgault S et al.Pituitaryadenylatecyclase-activating polypeptide and its receptors:20 yearsafter thediscovery.Pharmacol Rev 2009;61:283-357.
[0087] 11.Vaudry D,Gonzalez BJ,Basille M,Yon L,Fournier A,Vaudry H.Pituitaryadenylate cyclase-activating polypeptide and itsreceptors:from structure tofunctions.Pharmacol Rev 2000;52:269-324.
[0088] 12.Miyata A,Arimura A,Dahl R et al.Isolation of a novel 38residue-hypothalamic polypeptide which stimulates adenylate cyclasein pituitary cells.Biochem.Biophys.Res.Commun.1989;164:567-74.
[0089] 13.Han P,Liang W,Baxter LC et al.Pituitary adenylatecyclase-activating polypeptide is reduced in Alzheimer disease.Neurology 2014;82:1724-8.
[0090] 14.Han P,Caselli RJ,Baxter L et al.Association of pituitaryadenylatecyclase-activating polypeptide with cognitive decline in mildcognitiveimpairment due to Alzheimer disease.JAMA Neurol 2015;72:333-9.
[0091] 15.Jack C,Bennett D,Blennow K et al.A / T / N:An unbiaseddescriptiveclassification scheme for Alzheimer disease biomarkers.Neurology 2016;87:539-47.
[0092] 16.Saman S,Kim W,Raya M et al.Exosome-associated tau issecreted intauopathy models and is selectively phosphorylated in cerebrospinal fluid inearly Alzheimer disease.The Journal of biological chemistry 2012;287:3842-9.
[0093] 17.Cohen AD,Klunk WE.Early detection of Alzheimer's disease using PiBand FDG PET.Neurobiol.Dis.2014;72Pt A:117-22.
[0094] 18.Jack CR,Jr.,Lowe VJ,Senjem ML et al.11C PiB and structural MRIprovide complementary information in imaging of Alzheimer's disease andamnestic mild cognitive impairment.Brain2008;131:665-80.
[0095] 19. Rowe CC, Ellis KA, Rimajova M et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 2010; 31: 1275-83.
[0096] 20. Tian Jinzhou, Jie Hengge, Wang Luning, et al. Chinese Alzheimer's disease and dementia diagnosis and treatment guidelines 2020 edition. Chinese Journal of Geriatrics 2021; 40: 269-283.
[0097] 21. Sáenz-Cuesta M, Arbelaiz A, Oregi A et al. Methods for extracellularvesicles isolation in a hospital setting. Front. Immunol. 2015; 6:50.
[0098] 22.Jia L, Zhu M, Kong C et al. Blood neuro-exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage. Alzheimer's&dementia: the journal of the Alzheimer's Association2020.
[0099] 23.Fiandacaa MS, Kapogiannisb D, Mapstonec M et al. Identification ofpreclinical Alzheimer's disease by a profile of pathogenic proteins inneurally derived blood exosomes:Acase-control study.Alzheimer's&dementia:thejournal of the Alzheimer's Association 2015;11:600-7.e1.
[0100] 24.Jia L,Qiu Q,Zhang H et al.Concordance between the assessment of Aβ42,T-tau,and P-T181-tau in peripheral blood neuronal-derived exosomes andcerebrospinal fluid.Alzheimer's&dementia:the journal of the Alzheimer'sAssociation 2019;15:1071-1080.
[0101] 25.Goetzl E,Boxer A,Schwartz J et al.Low neural exosomallevels ofcellular survival factors in Alzheimer's disease.Annals ofclinical andtranslational neurology 2015;2:769-73.
[0102] 26.Kapogiannis D,Boxer A,Schwartz JB et al.Dysfunctionallyphosphorylated type 1 insulin receptor substrate in neural-derivedblood exosomes ofpreclinical Alzheimer's disease.FASEB journal:official publication of theFederation of American Societies forExperimental Biology 2015;29:589-96.
[0103] 27.FauréJ,Lachenal G,Court M et al.Exosomes are released byculturedcortical neurones.Mol.Cell.Neurosci.2006;31:642-8.
[0104] 28.Shi M,Liu C,Cook TJ et al.Plasma exosomalα-synuclein islikely CNS-derived and increased in Parkinson's disease.ActaNeuropathol.2014;128:639-650.
[0105] 29.Shi M,Liu C,Cook TJ et al.CNS tau efflux via exosomes islikelyincreased in Parkinson's disease but not in Alzheimer's disease.Alzheimer's&dementia:the journal of the Alzheimer's Association2016;12:1125-1131.
[0106] 30.Mustapic M,Eitan E,Werner J et al.Plasma ExtracellularVesiclesEnriched for Neuronal Origin:A Potential Window intoBrain PathologicProcesses.Frontiers in neuroscience 2017;11:278.
[0107] 31.Fitz NF,Wang J,Kamboh MI,Koldamova R,Lefterov I.Small nucleolarRNAs in plasma extracellular vesicles and theirdiscriminatory power asdiagnostic biomarkers of Alzheimer's disease.Neurobiol.Dis.2021;159:105481.
[0108] 32.Song S,Lee JU,Jeon MJ,Kim S,Sim SJ.Detection ofmultiplex exosomalmiRNAs for clinically accurate diagnosis ofAlzheimer's disease using label-free plasmonic biosensor based onDNA-Assembled advanced plasmonic architecture.Biosens.Bioelectron.2022;199:113864.
[0109] 33.Haddad M,Perrotte M,Ben Khedher MR et al.Levels of Receptor forAdvanced Glycation End Products and Glyoxalase-1in the Total CirculatingExtracellular Vesicles from Mild Cognitive Impairment and Different Stages ofAlzheimer's Disease Patients.J.Alzheimers Dis.2021;84:227-237.
[0110] 34.Picciolini S,Gualerzi A,Carlomagno C et al.An SPRi-based biosensorpilot study:Analysis of multiple circulating extracellular vesicles andhippocampal volume in Alzheimer's disease.J.Pharm.Biomed.Anal.2021;192:113649.
[0111] 35.Théry C, et al., Minimal information for studies of extracellular vesicles 2018(MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.J ExtracellVesicles.2018;7(1):1535750.
[0112] 36. Cocucci E, Meldolesi J. Ectosomes and exosomes: shedding theconfusion between extracellular vesicles. Trends Cell Biol. 2015; 25(6): 364-372.
[0113] Although the specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art. According to all the teachings disclosed, various modifications and replacements can be made to those details, and these changes are all within the protection scope of the present invention. The full scope of the present invention is given by the attached claims and any equivalents thereof.
Claims
1. Use of PACAP protein in exosomes derived from the nervous system or a reagent for detecting PACAP protein in exosomes derived from the nervous system in the preparation of a drug for diagnosing Alzheimer's disease.
2. The use according to claim 1, wherein The exosomes derived from the nervous system are brain-derived exosomes, such as exosomes derived from the pituitary gland.
3. The use according to any one of claims 1 to 2, wherein The amino acid sequence of the PACAP protein is shown in SEQ ID NO: 1 and / or SEQ ID NO:
2.
4. The use according to any one of claims 1 to 3, wherein The reagent for detecting PACAP protein in exosomes derived from the nervous system includes: (1) Reagents for extracting exosomes from the peripheral blood of a subject; (2) reagents for isolating or enriching exosomes or their contents from the nervous system; and / or (3) Reagents for measuring the concentration or content of PACAP protein.
5. The use according to any one of claims 1 to 4, wherein In item (1), the reagent for extracting exosomes from the peripheral blood of a subject includes Exoquick reagent.
6. The use according to any one of claims 1 to 5, wherein In item (2), the reagent for separating or enriching exosomes derived from the nervous system includes NCAM antibody or L1CAM antibody.
7. The use according to any one of claims 1 to 6, wherein In item (3), the reagent for determining the concentration or content of PACAP protein includes an ELISA reagent or an immunoblotting reagent for determining PACAP.
8. The use according to any one of claims 1 to 7, wherein The PACAP protein concentration of the subjects was compared with the cutoff value of the receiver operating curve of the exosomal PACAP protein concentration between AD and non-AD control groups: If the subject's PACAP protein concentration was greater than or equal to the cutoff value, the risk of AD was judged to be high; If the subject’s PACAP protein concentration is less than the cutoff value, the risk of AD is judged to be low; Preferably, the number of AD subject samples and non-AD subject samples for drawing the working curve is independently greater than or equal to 10, greater than or equal to 20, greater than or equal to 30, greater than or equal to 50, greater than or equal to 80, greater than or equal to 100, greater than or equal to 200 or greater than or equal to 500.
9. The use according to any one of claims 1 to 8, wherein: If the subject's PACAP protein concentration is greater than or equal to the threshold, the risk of AD is judged to be high; If the subject’s PACAP protein concentration is less than the threshold, the risk of AD is judged to be low; Preferably, the threshold value is 4.5-5.5 ng / mL, 4.6-5.4 ng / mL, 4.7-5.3 ng / mL, 4.8-5.2 ng / mL, 4.9-5.1 ng / mL, 4.9-5.0 ng / mL, 4.9 ng / mL or 4.9412 ng / mL.
10. The use according to any one of claims 1 to 9, wherein: If the PACAP protein concentration of the subject is greater than or equal to that of the healthy subject, the risk of AD is judged to be higher; If the PACAP protein concentration of the subject is lower than that of a healthy subject, the risk of AD is judged to be lower.
